Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at Centogene, Allelica, ERS Genomics, More

Centogene: Kim Stratton, Andreas Busch

Centogene has nominated Kim Stratton as its permanent CEO. She had taken over as interim CEO from Andrin Oswald in December, who had stepped down to take a medical leave of absence. Stratton was most recently CEO of Orphazyme. Before that, she was head of international commercial for the specialty and rare disease portfolio of Shire Pharmaceuticals, and prior to that, she held various senior management roles at Novartis.

In addition, Centogene has nominated Andreas Busch to its supervisory board. Since 2019, he has been chief innovation officer and CSO at Cyclerion Therapeutics. Prior to that, he was head of R&D and CSO at Shire, and before that, he held various senior leadership positions at Bayer, including head of drug discovery and member of the executive committee for the pharmaceuticals division. Busch holds a Ph.D. in pharmacology from Goethe University Frankfurt in Germany.

Allelica: Scientific Advisory Board

Allelica has added Noura Abul-Husn, Robert Green, Gordon Huggins, and Aleksandar Rajkovic to its scientific advisory board.

Abul-Husn is the founding chief of the Division of Genomic Medicine at the Icahn School of Medicine, and clinical director of the school's Institute for Genomic Health. She is an associate professor of medicine and genetics and board certified in internal medicine and medical genetics.

Green is a professor of medicine at Harvard Medical School and directs the Genomes 2 People research program at Brigham and Women's Hospital, Broad Institute, and Ariadne Labs.

Huggins is director of the Molecular Cardiology Research Institute Center for Translational Pharmacology and Genomics and an associate professor at Tufts University School of Medicine. He has previously directed the genetic ancillary study for the Look AHEAD trial, and led the NHLBI Heart Failure Network program at Tufts. He has also directed participation in the Dilated Cardiomyopathy Genetics Consortium.

Rajkovic is the medical director and chief of the Center for Genetic and Genomic Medicine in the UCSF Health System, and previously served as chief of medical and laboratory genetics at the University of Pittsburgh Medical Center.

ERS Genomics: Ralph Vogelsang

Ralph Vogelsang has been named senior director for business development and licensing at gene editing intellectual property company ERS Genomics. He joins the firm from Pacific Biosciences, where he held various positions in sales, scientific support, and business development. Previously, he worked in sales for Applied Biosystems.

For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.